| Drug Name |
Solifenacin succinate |
| Drug ID |
BADD_D02054 |
| Description |
Solifenacin is a competitive muscarinic receptor antagonist indicated to treat an overactive bladder with urinary incontinence, urgency, and frequency.[L7511] It has a long duration of action as it is usually taken once daily.[L7511]
Solifenacin was granted FDA approval on 19 November 2004.[L7511] |
| Indications and Usage |
Solifenacin tablets are indicated to treat an overactive bladder with urinary incontinence, urgency, and frequency.[L7511] |
| Marketing Status |
approved |
| ATC Code |
G04BD08 |
| DrugBank ID |
DB01591
|
| KEGG ID |
D01269
|
| MeSH ID |
D000069464
|
| PubChem ID |
216457
|
| TTD Drug ID |
D0L4YD
|
| NDC Product Code |
51248-151; 0527-1933; 0591-3795; 71335-1729; 65862-800; 51407-472; 60505-4702; 62332-193; 63629-8869; 69539-050; 0591-3796; 42185-7071; 51407-228; 62332-192; 67877-528; 69238-1309; 69539-051; 63629-8870; 69367-240; 71205-987; 42291-740; 51248-250; 63629-8867; 63629-8868; 65862-878; 67877-527; 0527-1934; 71205-583; 72205-020; 53747-067; 57438-8096; 62512-0054; 64552-4022; 64552-4086; 65372-1158; 67835-0018; 31722-028; 35561-286; 50228-427; 50228-428; 60505-4703; 69238-1308; 69367-296; 71205-539; 71205-559; 71205-561; 71205-934; 51407-471; 68462-387; 69844-047; 69844-048; 70518-3156; 14501-0053; 36974-0071; 46708-193; 65862-879; 29300-329; 46708-192; 51248-150; 63629-8532; 71205-540; 72205-021; 72606-009; 53104-7705; 59285-006; 27241-038; 29300-328; 31722-027; 68462-386; 69367-239; 71205-986; 72606-010; 66039-858; 27241-037 |
| UNII |
KKA5DLD701
|
| Synonyms |
Solifenacin Succinate | Succinate, Solifenacin | Quinuclidin-3'-yl-1-phenyl-1,2,3,4-tetrahydroisoquinoline-2-carboxylate monosuccinate | YM905 | YM 905 | 905, YM | Vesicare | Solifenacin | 2(1H)-Isoquinolinecarboxylic acid, 3,4-dihydro-1-phenyl-,1- azabicyclo(2.2.2)oct-3-yl ester, (R-(R*,S*))- |
